The
endocannabinoid system regulates energy homeostasis through G protein — coupled cannabinoid - 1 receptors5, 6 located in the central nervous system and in various peripheral tissues, including adipose tissue, muscle, the gastrointestinal tract, and the liver.7 While peripheral cannabinoid - 1 receptor activation decreases adiponectin
production in adipocytes, 8 central cannabinoid - 1 receptor activation in preclinical studies stimulates eating, decreases muscle, and stimulates hepatic and adipose tissue lipogenic pathways in animal models of obesity.9 In genetic and diet - induced obesity, rimonabant, a selective cannabinoid - 1 receptor blocker, reduces overactivation of the central8, 10 and peripheral11, 12
endocannabinoid system8, 10,13 and prevents weight gain and associated metabolic disorders, thus revealing a novel strategy for the treatment of obesity and related cardiometabolic disorders.